C3-Bicyclic Glutarimide Degrons for Stronger Cereblon Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies for targeted protein degradation, such as those using thalidomide and its analogues, have limitations in effectively modulating the activity of cereblon E3 ubiquitin ligase for therapeutic applications, particularly in treating disorders like cancer and multiple myeloma.
Innovation Solution
Development of cereblon binding compounds with specific bicyclic substituents at the C3 position of glutarimide, known as Degrons, which enhance the interaction with cereblon, facilitating the ubiquitination and degradation of target proteins through the ubiquitin-proteasome pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thalidomide and its analogues are used to bind cereblon, then immunomodulatory and antineoplastic activity is achieved, but the ability to effectively modulate cereblon activity for therapeutic applications is limited
Solution Approach 1:
The patent introduces specific bicyclic substituents at the C3 position of the glutarimide core structure to locally enhance binding affinity and selectivity for cereblon. This local structural modification improves therapeutic efficacy while maintaining the overall glutarimide framework that provides baseline cereblon binding capability.
Solution Approach 2:
The patent systematically varies structural parameters including the type of bicyclic substituent (aryl, heteroaryl, carbocyclic), substitution patterns, and linker characteristics to optimize cereblon binding affinity and degradation activity. These parameter changes enable fine-tuning of the compounds' ability to modulate cereblon activity for different therapeutic applications.
2Productivity
If current thalidomide-based compounds are used, then some protein degradation activity is achieved, but effective targeted degradation of disease-associated proteins is insufficient
Solution Approach 1:
The patent creates composite molecular structures by combining the glutarimide core (which binds cereblon) with specific bicyclic substituent groups. This composite structure synergistically enhances both the binding affinity to cereblon and the ability to induce degradation of target proteins, achieving superior therapeutic effectiveness compared to thalidomide alone.
Solution Approach 2:
The patent divides the molecule into functional segments: the glutarimide core that binds cereblon, the bicyclic substituent that enhances binding and selectivity, and linker regions that facilitate protein degradation. This segmentation allows independent optimization of each functional element to maximize overall degradation efficiency and therapeutic effect.
Data Source
AI summary
This invention provides Degron compounds which bind to cereblon which is a component of the E3 ubiquitin ligase. The Degrons provided herein can be used to modulate the activity of cereblon either alone or as covalently linked to a Tail. Alternatively, the Degron can be linked to a Targeting Ligand which binds to a Target Protein for protein degradation.